215
Participants
Start Date
May 1, 2019
Primary Completion Date
August 12, 2020
Study Completion Date
August 12, 2020
Semaglutide
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Novo Nordisk Investigational Site, Atherstone
Novo Nordisk Investigational Site, Berkshire
Novo Nordisk Investigational Site, Bradford
Novo Nordisk Investigational Site, Brighton
Novo Nordisk Investigational Site, Camberley
Novo Nordisk Investigational Site, Cambridgeshire
Novo Nordisk Investigational Site, Chiswick
Novo Nordisk Investigational Site, Co Durham
Novo Nordisk Investigational Site, Coventry
Novo Nordisk Investigational Site, Darlington
Novo Nordisk Investigational Site, Dudley
Novo Nordisk Investigational Site, Durham
Novo Nordisk Investigational Site, Greenisland
Novo Nordisk Investigational Site, Halifax
Novo Nordisk Investigational Site, Hull
Novo Nordisk Investigational Site, Kettering
Novo Nordisk Investigational Site, Leicester
Novo Nordisk Investigational Site, Leicestershire
Novo Nordisk Investigational Site, Lincs
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, Machester
Novo Nordisk Investigational Site, Manchester
Novo Nordisk Investigational Site, Merseyside
Novo Nordisk Investigational Site, Nuneaton
Novo Nordisk Investigational Site, Rayleigh
Novo Nordisk Investigational Site, Rhyl
Novo Nordisk Investigational Site, South Shields
Novo Nordisk Investigational Site, Southampton
Novo Nordisk Investigational Site, Walton on Thames
Novo Nordisk Investigational Site, Watford
Novo Nordisk Investigational Site, Wellingborough
Lead Sponsor
Novo Nordisk A/S
INDUSTRY